Garibotto Giacomo, Sofia Antonella, Balbi Manrico, Procopio Vanessa, Villaggio Barbara, Tarroni Alice, Di Martino Massimiliano, Cappelli Valeria, Gandolfo Maria Teresa, Valli Alessandro, Verzola Daniela
Department of Internal Medicine, Division of Nephrology, Genoa University, Genoa, Italy.
Cytokine. 2007 Jan;37(1):51-4. doi: 10.1016/j.cyto.2007.02.015. Epub 2007 Apr 8.
Chronic elevation of circulating Interleukin-6 (IL-6) is observed in elderly individuals as well as in several illnesses, including chronic kidney diseases. A number of cells and tissues possess the ability to metabolize significant amounts of IL-6 in vitro. However, information on signals and mechanisms by which IL-6 is removed from blood in humans is still incomplete. To assess the individual role of splanchnic organs and kidney on IL-6 inter-organ exchange we used the IL-6 mass-balance technique across the hepato-splanchnic bed and kidney in six subjects with normal renal and liver function undergoing diagnostic venous catheterizations. Both in the hepatic and renal veins IL-6 levels were significantly lower (p=0.041 and 0.038, respectively), than in the artery. The fractional extraction of IL-6, i.e., the percentage of arterial IL-6 extracted after a single pass, was greater across the splanchnic organs (18%) than across the kidney (8%). Accordingly, IL-6 plasma clearance across splanchnic organs was greater than across the kidney and the sum of kidney and splanchnic removal accounted for as much as 63% of the estimated adipocyte IL-6 release. Our data demonstrate that, although the individual contribution to removal is different, both splanchnic organs and kidneys affect in a significant way the disposal of IL-6 in humans. According, both liver and kidney dysfunction could affect the handling of this proinflammatory cytokine and favour a chronic inflammatory response.
在老年人以及包括慢性肾病在内的多种疾病中，均可观察到循环白细胞介素-6（IL-6）水平长期升高。许多细胞和组织在体外具有代谢大量IL-6的能力。然而，关于人类血液中IL-6清除的信号和机制的信息仍不完整。为了评估内脏器官和肾脏在IL-6器官间交换中的个体作用，我们对6名肝肾功能正常且正在接受诊断性静脉置管的受试者，采用了跨肝内脏床和肾脏的IL-6质量平衡技术。肝静脉和肾静脉中的IL-6水平均显著低于动脉（分别为p=0.041和0.038）。IL-6的分数提取率，即单次通过后动脉IL-6被提取的百分比，在内脏器官中（18%）高于肾脏（8%）。因此，内脏器官对IL-6的血浆清除率高于肾脏，肾脏和内脏清除的总和占估计脂肪细胞IL-6释放量的63%。我们的数据表明，尽管个体对清除的贡献不同，但内脏器官和肾脏均对人类体内IL-6的处置有显著影响。因此，肝脏和肾脏功能障碍均可能影响这种促炎细胞因子的处理，并促进慢性炎症反应。
